Stock Analysis on Net
AI Tokens
Stock Analysis on Net

Zoetis Inc. (NYSE:ZTS)

This company has been moved to the archive! The financial data has not been updated since May 2, 2024.

Current Ratio
since 2012

Microsoft Excel

Calculation

Zoetis Inc., current ratio, long-term trends, calculation

Microsoft Excel

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).

1 US$ in millions

The short-term liquidity position of the organization has remained robust between 2012 and 2023, characterized by a current ratio that consistently exceeded 2.0. This indicates a sustained ability to cover short-term obligations with current assets, maintaining a significant margin of safety throughout the analyzed period.

Current Asset Progression
Current assets exhibited a general upward trajectory, increasing from 2,864 million US dollars in 2012 to 6,343 million US dollars by 2023. A peak in liquidity was observed in 2022, where assets reached 7,506 million US dollars, representing a substantial growth in short-term resource availability over the decade.
Current Liability Fluctuations
Current liabilities showed greater volatility than assets. While liabilities remained relatively stable between 1,000 and 2,000 million US dollars for much of the period, a significant spike occurred in 2022, reaching 3,167 million US dollars. This increase correlates with the lowest current ratio observed in the latter half of the period.
Current Ratio Volatility and Trends
The current ratio fluctuated between a minimum of 2.15 in 2015 and a maximum of 3.86 in 2021. Notable peaks occurred in 2017 (3.85) and 2021 (3.86), reflecting periods of exceptionally high liquidity relative to short-term debt. The decline to 2.37 in 2022 was primarily driven by the surge in current liabilities, followed by a recovery to 3.36 in 2023 as liabilities decreased to 1,889 million US dollars.

AI Ask an analyst for more

My previous chats

Add tokens

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?

Comparison to Competitors

Zoetis Inc., current ratio, long-term trends, comparison to competitors

Microsoft Excel
Zoetis Inc. AbbVie Inc. Amgen Inc. Bristol-Myers Squibb Co. Danaher Corp. Eli Lilly & Co. Gilead Sciences Inc. Johnson & Johnson Merck & Co. Inc. Pfizer Inc. Regeneron Pharmaceuticals Inc. Thermo Fisher Scientific Inc. Vertex Pharmaceuticals Inc.
Dec 31, 2023 3.36 0.87 1.65 1.43 1.68 0.94 1.43 1.16 1.25 0.91 5.69 1.75 3.99
Dec 31, 2022 2.37 0.96 1.41 1.25 1.89 1.05 1.29 0.99 1.47 1.22 5.06 1.48 4.83
Dec 31, 2021 3.86 0.79 1.59 1.52 1.43 1.23 1.27 1.35 1.27 1.40 3.56 1.50 4.46
Dec 31, 2020 3.05 0.84 1.81 1.58 1.86 1.40 1.40 1.21 1.02 1.35 3.63 2.13 4.33
Dec 31, 2019 2.63 3.18 1.44 1.60 5.19 1.16 3.10 1.26 1.24 0.88 3.67 1.92 3.61
Dec 31, 2018 3.60 0.98 2.79 1.61 1.47 1.73 3.38 1.47 1.17 1.57 4.47 1.73 3.43
Dec 31, 2017 3.85 1.28 5.49 1.55 1.43 1.32 2.74 1.41 1.33 1.35 3.82 1.34 3.28
Dec 31, 2016 3.03 1.65 4.11 1.55 0.97 1.37 2.22 2.47 1.78 1.25 2.56 1.44 2.31
Dec 31, 2015 2.15 1.50 4.44 1.30 1.27 1.53 2.50 2.17 1.55 1.49 3.59 1.38 2.78
Dec 31, 2014 3.19 1.41 4.95 1.73 1.75 1.09 3.07 2.36 1.77 2.67 3.31 1.22 4.20
Dec 31, 2013 2.37 2.59 3.44 1.52 2.01 1.47 1.15 2.20 2.00 2.41 6.01 3.16 3.99
Dec 31, 2012 2.55 2.27 3.81 1.15 1.80 1.55 1.44 1.90 1.90 2.15 7.37 2.31 3.67

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).

Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)

Zoetis Inc., current ratio, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)

Microsoft Excel
Zoetis Inc. Pharmaceuticals, Biotechnology & Life Sciences
Dec 31, 2023 3.36 1.27
Dec 31, 2022 2.37 1.30
Dec 31, 2021 3.86 1.36
Dec 31, 2020 3.05 1.37
Dec 31, 2019 2.63 1.66
Dec 31, 2018 3.60 1.71
Dec 31, 2017 3.85 1.74
Dec 31, 2016 3.03 1.91
Dec 31, 2015 2.15 1.90
Dec 31, 2014 3.19 2.19
Dec 31, 2013 2.37 2.17
Dec 31, 2012 2.55 2.04

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).

Comparison to Industry (Health Care)

Zoetis Inc., current ratio, long-term trends, comparison to industry (health care)

Microsoft Excel
Zoetis Inc. Health Care
Dec 31, 2023 3.36 1.23
Dec 31, 2022 2.37 1.23
Dec 31, 2021 3.86 1.31
Dec 31, 2020 3.05 1.30
Dec 31, 2019 2.63 1.48
Dec 31, 2018 3.60 1.52
Dec 31, 2017 3.85 1.55
Dec 31, 2016 3.03 1.73
Dec 31, 2015 2.15 1.70
Dec 31, 2014 3.19 1.92
Dec 31, 2013 2.37 1.96
Dec 31, 2012 2.55 1.84

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).